Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Imaging-Based Biomarkers in Neurological Diseases-A Critical Review

Version 1 : Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (11:26:01 CEST)

How to cite: Kale, M.B.; Wankhede, N.L.; Taksande, B.G.; Upaganlawar, A.B.; Umekar, M.J.; Koppula, S.; Kopalli, S.R. Imaging-Based Biomarkers in Neurological Diseases-A Critical Review. Preprints 2023, 2023090536. https://doi.org/10.20944/preprints202309.0536.v1 Kale, M.B.; Wankhede, N.L.; Taksande, B.G.; Upaganlawar, A.B.; Umekar, M.J.; Koppula, S.; Kopalli, S.R. Imaging-Based Biomarkers in Neurological Diseases-A Critical Review. Preprints 2023, 2023090536. https://doi.org/10.20944/preprints202309.0536.v1

Abstract

Imaging-based biomarkers have developed as an effective tool in neurology, providing vital understandings of the structural, functional, and molecular changes associated with neurological disorders. Imaging techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and computed tomography (CT) have been widely employed to record disease-related alterations in the brain. These techniques provide a wide range of biomarkers, such as functional connectivity patterns, volumetric measurements, molecular imaging agents, and perfusion parameters, enabling the correct identification of neurological disorders. These biomarkers have proven useful in early diagnosis, disease progression tracking, therapy response prediction, and surgical planning. This review emphasizes the various obstacles and limitations that are associated with imaging-based biomarkers. Technical constraints, standardization obstacles, ethical concerns, regulatory challenges, and cost-effectiveness concerns all offer substantial barriers to wider use. It is vital to overcome these challenges if imaging biomarkers are to be successfully integrated into routine clinical practice. Imaging technology advancements like high-resolution imaging, multimodal imaging, and artificial intelligence-based analysis hold immense promise for imaging-based biomarkers in the future. While more study and standardization are needed, their ongoing development and integration into clinical practice have the potential to revolutionize the diagnosis, treatment, and management of neurological disorders, resulting in better patient care and outcomes.

Keywords

PET; MRI; SPECT; CT; Depression; Epilepsy; Atrophy

Subject

Biology and Life Sciences, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.